degeneration amd product overview iluvien for dme nadph oxidase inhibitors full prescribing information iluvien patent notices investor relations investor overview events & presentation corporate governance financial information stock information investor faqs contact investor relations news about us management team board of directors careers contact us compliance program retinal disease is our focus moving the back of the eye to the forefront of research and development . learn more 2016 alimera sciences . this site intended for us residents only . legal statement privacy policy safe harbor privacy policy contact us follow us on facebook twitter you tube rss